Evidence map›Paper›PMID 23893332›Full record

Trial reportDiabetologia2013

The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes.

David Z I Cherney, Heather N Reich, James W Scholey, Denis Daneman, Farid H Mahmud, Ronnie L H Har, Etienne B Sochett

Open access · bronzeAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Diabetologia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Article
  4. Article
  5. Article
  6. Immunologic Effects of the Renin-Angiotensin System.Journal of the American Society of Nephrology : JASN · 2017
    Review
  7. Review
  8. Early diabetic nephropathy in type 1 diabetes: new insights.Current opinion in endocrinology, diabetes, and obesity · 2014
    Review
  9. Article
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

David Z I CherneyDivision of Nephrology, University Health Network - Toronto General Hospital, Banting and Best Diabetes Centre, University of Toronto, 585 University Ave, 8N-845, Toronto, ON M5G 2N2, Canada. david.cherney@uhn.on.ca
Heather N Reich
James W Scholey
Denis Daneman
Farid H Mahmud
Ronnie L H Har
Etienne B Sochett
Toronto General Hospital · CASickKids Foundation · CAUniversity Health Network · CAUniversity of Toronto · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

aims/hypothesisAcute clamped hyperglycaemia activates the renin-angiotensin-aldosterone system (RAAS) and increases the urinary excretion of inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Our objective was to determine whether blockade of the RAAS would blunt the effect of acute hyperglycaemia on urinary cytokine/chemokine excretion, thereby giving insights into potentially protective effects of these agents prior to the onset of clinical nephropathy.

methodsBlood pressure, renal haemodynamic function (inulin and para-aminohippurate clearances) and urinary cytokines/chemokines were measured after 6 h of clamped euglycaemia (4-6 mmol/l) and hyperglycaemia (9-11 mmol/l) on two consecutive days in patients with type 1 diabetes mellitus (n = 27) without overt nephropathy. Measurements were repeated after treatment with aliskiren (300 mg daily) for 30 days.

resultsBefore aliskiren, clamped hyperglycaemia increased filtration fraction (from 0.188 ± 0.007 to 0.206 ± 0.007, p = 0.003) and urinary fibroblast growth factor-2 (FGF2), IFN-α2 and macrophage-derived chemokine (MDC) (p < 0.005). After aliskiren, the filtration fraction response to hyperglycaemia was abolished, resulting in a lower filtration fraction after aliskiren under clamped hyperglycaemic conditions (p = 0.004), and none of the biomarkers increased in response to hyperglycaemia. Aliskiren therapy also reduced levels of urinary eotaxin, FGF2, IFN-α2, IL-2 and MDC during clamped hyperglycaemia (p < 0.005). CONCLUSIONS/

interpretationThe increased urinary excretion of inflammatory cytokines/chemokines in response to acute hyperglycaemia is blunted by RAAS blockade in humans with uncomplicated type 1 diabetes mellitus.

Indexed as

AdultAmidesChemokinesCytokinesDiabetes Mellitus, Type 1FemaleFumaratesHumansHyperglycemiaInsulinMalep-Aminohippuric AcidProteomicsYoung AdultaliskirenAmidesChemokinesCytokinesFumaratesInsulinp-Aminohippuric Acid

Identifiers

PMID23893332
OpenAlexW2004235385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.